Depending on the therapeutic context, biologics have proven to be surprisingly immunogenic. After years of thorough study of the parameters influencing immunogenicity, EpiVax uses proprietary, state-of-the-art, immunoinformatics tools and in vitro techniques to predict the potential immunogenicity of proteins, whether these proteins are administered for therapeutic purposes (as in enzymes, monoclonals, replacement proteins) or as vaccines.
Immunogenicity screening and placement of drug candidates on an immunogenicity scale is now used as a means of comparing one protein therapeutic (or mAb) to another, so as to select the best lead to carry forward from preclinical to clinical development, thus reducing the risk of failure due to immunogenicity in the clinical setting.
At the core of our approach to immunogenicity screening is the in silico analysis. Using the ISPRI toolkit we can analyze the immunogenic potential of a candidate protein in depth. Not only does this approach save time, but it allows us to move forward to lab validation or deimmunization in a targeted way. The fastest way to waste money is to go blindly into costly lab work.
Explore the tabs to the left for details on immunogenicity screening options.